Comprehensive Review of Lung Cancer by wuyunyi


									Comprehensive Review                                                                             Saturday, February 28, 2009, Atlanta, GA
  of Lung Cancer                                                                                 Buckhead Hotel Atlanta
                                                                                                 3405 Lenox Road NE, Atlanta, GA 30326
Statement of Need/Program Overview                                                               Telephone: (404) 261-9250
This program is intended to facilitate interaction among oncologists and
nurses interested in development of novel therapeutics for treatment of lung                     Program Director
cancer. In addition to multimodality therapy, adjuvant therapy, this sympo-
sium will present data of most promising emerging agents currently in devel-
                                                                                                 Chandra P. Belani, MD
opment for the treatment of lung cancer. There will be in-depth discussion                       Miriam Beckner Distinguished Professor of Medicine Penn State
of both antiangiogenic agents and inhibitors of EGFR pathways. Drugs that                        Milton S. Hershey Medical Center
target multiple signaling pathways will also be given significant focus.                          Penn State College of Medicine
Physician Continuing Medical Education                                                           Deputy Director, Penn State Cancer Institute, Hershey, PA
Accreditation Statement: This activity has been planned and implemented in ac-
cordance with the Essential Areas and policies of the Accreditation Council for Con-             Agenda Topics
tinuing Medical Education (ACCME) through the joint sponsorship of Postgraduate                   Novel Agents in Combination with Radiation Therapy for Lung Cancer
Institute for Medicine (PIM) and International Cancer Network. PIM is accredited by               Management of Stage III Disease: Multimodality Therapy for Lung Cancer
the ACCME to provide continuing medical education for physicians.
                                                                                                  Small Cell Lung Cancer: Novel Agents and Recent Advances
Credit Designation: Postgraduate Institute for Medicine designates this educational
activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)TM. Physicians should                   Targeting VEGF and EGFR in Lung Cancer
only claim credit commensurate with the extent of their participation in the activity.            Bevacizumab: Implications of Recent data in Non–Small-Cell Lung Cancer
Nursing Continuing Education                                                                      Small Molecule VEGF Receptor Tyrosine Kinase Inhibitors and Multikinase
Purpose: The purpose of this educational meeting is to assist healthcare providers                  Inhibitors in the Treatment of Lung Cancer
develop appropriate treatment strategies that minimize side effects and optimize                  Targeting EGFR-Monoclonal Antibodies and EGFR Tyrosine Kinase
outcomes in patients with lung cancer.
                                                                                                    Inhibitors in Lung Cancer
Accreditation Statements: CNA/ANCC
This educational activity for 5.5 contact hours is provided by Postgraduate Institute             State of the Art and Other Targeted Agents in Non–Small-Cell Lung Cancer
for Medicine (PIM).                                                                               First-Line Chemotherapy Options for Advanced Lung Cancer
PIM is an approved provider of continuing nursing education by the Colorado                       Second-line Chemotherapeutic Options for Lung Cancer
Nurses Association, an accredited approver by the American Nurses Credentialing
                                                                                                  Novel Agents in Lung Cancer: HDAC Inhibitors, Nab-Paclitaxel,
Center’s Commission on Accreditation.
                                                                                                    Bortezomib, and Others
Pharmacist Continuing Education
Accreditation Statement: Postgraduate Institute for Medicine is accredited by the Accredi-
tation Council for Pharmacy Education as a provider of continuing pharmacy education.
                                                                                                 Target Audience
                                                                                                  Medical Oncologists, Radiation Oncologists, Nurses, Pharmacists,
Credit Designation: Postgraduate Institute for Medicine designates each session of                Physician Assistants, Fellows in training
this continuing education activity for 1.8 contact hour(s) (0.18 CEUs) of the Ac-
creditation Council for Pharmacy Education. (Session I Universal Program Number                   Jointly sponsored by International Cancer Network and Postgraduate Institute for
809-999-09-001-L01-P; Session II Universal Program Number 809-999-09-002-                         Medicine
L01-P; Session III Universal Program Number 809-999-09-003-L01-P).

Saturday, February 28, 2009 - Atlanta, GA

First Name_______________________________ Middle Initial______ Last Name_______________________________________________
❑ Physician     ❑ Pa-C    ❑ Fellow    ❑ NP      ❑ PhD      ❑ Pharmacist    ❑ Industry   ❑ Nurse     ❑ Other

Mailing Address_____________________________________________________________________________________________________
City_______________________________________________ State___________________ Zip Code________________________________
Phone__________________________ Fax________________________ E-Mail_________________________________________________
Registration Fee
                                                                                                                                   Fax registration to:
Registration fee partially covers continental breakfast, lunch and syllabus book                                                   443-267-0016
❑ Physicians      $50.00                      ❑ Nurses, Pharmacists, others      $30.00
❑ Fellows         No Registration Fee         ❑ *Industry                        $325.00                                           Mail registration to:
                                                                                                                                   PO Box 116609
*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions
                                                                                                                                   Carrollton, TX 75011-6609
Payment may be made: ❑ MC ❑ Visa ❑ Discover ❑ Amex ❑ Check
Credit Card Number___________________________ Expiration Date_______________ Security code (AmEx on front)_________________
Name and address as it appears on Credit Card_____________________________________________________________________________
Register online at
Please make checks payable to International Cancer Network. Mail checks to PO Box 116609, Carrollton, TX 75011-6609
To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or
                             If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.

To top